With over 35 nationalities and a range of backgrounds represented in our Benevolent team, we aim to build an inclusive environment where our people can bring their authentic selves to work, be respected for who they are and the exceptional work they do. We welcome and actively encourage applications from all sections of society and are committed to offering equal employment opportunities regardless of sex, race, religion or belief, ethnic or national origin, marital, domestic or civil partnership status, sexual orientation, gender identity, parental status, disability, age, citizenship, or any other basis. We see our diversity as an asset as we tackle challenging problems that bridge the gap between drug discovery and technology.
This is an exciting opportunity to join an expanding group supporting a growing pipeline of projects. The team is looking for a motivated individual with a track record of working within project teams as the DMPK point of contact, who is able to show how they successfully influenced the progress of the teams they were a part of. Reporting to the Director of DMPK and In Vivo. You will play an important role in helping to shape the non-clinical PK/PD strategy for projects. You will be expected to engage fully in multi-functional collaborations to support profiling of lead compounds/drug candidates, building a clear picture of IVIVC PK/PD, and ultimately to ensure translation from in vitro data and in vivo non-clinical studies to the prediction of pharmacokinetics, efficacy and safety in patients.
We share a passion for being part of a mission that matters, and we are always looking for curious and collaborative people who share our values and want to be part of our journey. If that sounds like a fit for you, hit the apply button and join us.
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Our team will only contact you from the domain @benevolent.ai. If you receive a suspicious contact request, please email firstname.lastname@example.org. Thank you.